Acura Pharmaceuticals (ACUR)
Q2 2012 Earnings Call
July 31, 2012 8:30 am ET
Robert B. Jones - Chief Executive Officer, President and Director
Peter A. Clemens - Chief Financial Officer, Principal Accounting officer, Senior Vice President of Investor Relations and Secretary
Michael Kallai Tong - Wells Fargo Securities, LLC, Research Division
Kevin Kedra - Gabelli & Company, Inc.
Robert Cummins Hazlett - Roth Capital Partners, LLC, Research Division
Good day, everyone, and welcome, ladies and gentlemen, to the Acura Pharmaceutical's Conference Call. As a reminder, today's call is being recorded. [Operator Instructions] At this time, I'd like to turn the call over to David Carey of Lazar Partners. Please go ahead, sir.
Thank you. Before we begin, I'd like to remind you that any discussion that takes place during this conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current view of future events and operations including, but not limited to, statements pertaining to the company's expectations regarding OXECTA and other products licensed to Pfizer, the company's product development pipeline, commercial plans for the NEXAFED product, the commercial potential of the company's products and plans to maximize this potential, future product sales and financial results and the company's strategy for long-term growth. Forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Certain factors that may cause actual results to differ materially from the forward-looking statements are discussed in the company's press release issued yesterday evening and the Risk Factors section and other sections of the company's Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.